Abzena’s acquisition of PacificGMP in September for £5.5m and recent purchase of TCRS for £10m significantly enhances its technology and services offering, particularly GMP manufacturing capacity. The deals are immediately accretive to the group on an EBITDA basis, with full impact on revenues and EBIT margins expected in FY17. To fund the TCRS acquisition, the company completed a £20m (net) share placement. The Abzena inside antibody clinical pipeline has increased to
15 Dec 2015
Rapid M&A and pipeline progress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Rapid M&A and pipeline progress
Abzena (ABZA:LON) | 0 0 (-0.9%) | Mkt Cap: 54.0m
- Published:
15 Dec 2015 -
Author:
Linda Pomeroy -
Pages:
8
Abzena’s acquisition of PacificGMP in September for £5.5m and recent purchase of TCRS for £10m significantly enhances its technology and services offering, particularly GMP manufacturing capacity. The deals are immediately accretive to the group on an EBITDA basis, with full impact on revenues and EBIT margins expected in FY17. To fund the TCRS acquisition, the company completed a £20m (net) share placement. The Abzena inside antibody clinical pipeline has increased to